FHOD1 is upregulated in glioma cells and attenuates ferroptosis of glioma cells by targeting HSPB1 signaling
CNS Neuroscience & Therapeutics · 2023
DOI: 10.1111/cns.14264 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2023. Verfasst von Fan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Ferroptosis, Glioma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Hunan Province.
Abstract (Originalsprache)
Background
As a new type of regulatory cell death, ferroptosis has been proven to be involved in cancer pathogenesis and therapeutic response. However, the detailed roles of ferroptosis or ferroptosis‐associated genes in glioma remain to be clarified.
Methods
Here, we performed the TMT/iTRAQ‐Based Quantitative Proteomic Approach to identify the differentially expressed proteins between glioma specimens and adjacent tissues. Kaplan–Meier survival was used to estimate the survival values. We also explored the regulatory roles of abnormally expressed formin homology 2 domain‐containing protein 1 (FHOD1) in glioma ferroptosis sensitivity.
Results
In our study, FHOD1 was identified to be the most significantly upregulated protein in glioma tissues. Multiple glioma datasets revealed that the glioma patients with low FHOD1 expression displayed favorable survival time. Functional analysis proved that the knockdown of FHOD1 inhibited cell growth and improved the cellular sensitivity to ferroptosis in glioma cells T98G and U251. Mechanically, we found the up‐regulation and hypomethylation of HSPB1, a negative regulator of ferroptosis, in glioma tissues. FHOD1 knockdown could enhance the ferroptosis sensitivity of glioma cells via up‐regulating the methylated heat‐shock protein B (HSPB1). Overexpression of HSPB1 significantly reversed FHOD1 knockdown‐mediated ferroptosis.
Conclusions
In summary, this study demonstrated that the FHOD1‐HSPB1 axis exerts marked regulatory effects on ferroptosis, and might affect the prognosis and therapeutic response in glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Physiology, School of Basic Medical Science, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- State Key Laboratory of Silkworm Genome Biology, Medical Research Institute, Southwest University, Chongqing, China.
- Pritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois, USA.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Yuanliang Yan
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Hunan Province
Zitieren
APA
Zhang, F., Wu, L., Feng, S., Zhao, Z., Zhang, K., Thakur, A., Xu, Z., Liang, Q., Liu, Y., Liu, W., & Yan, Y. (2023). FHOD1 is upregulated in glioma cells and attenuates ferroptosis of glioma cells by targeting HSPB1 signaling. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14264
Vancouver
Zhang F, Wu L, Feng S, Zhao Z, Zhang K, Thakur A, et al. FHOD1 is upregulated in glioma cells and attenuates ferroptosis of glioma cells by targeting HSPB1 signaling. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14264
BibTeX
@article{Zhang2023,
author = {Zhang, Fan and Wu, Lixiang and Feng, Songshan and Zhao, Zijin and Zhang, Kui and Thakur, Abhimanyu and Xu, Zhijie and Liang, Qiuju and Liu, Yuanhong and Liu, Wei and Yan, Yuanliang},
title = {FHOD1 is upregulated in glioma cells and attenuates ferroptosis of glioma cells by targeting HSPB1 signaling},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
doi = {10.1111/cns.14264}
}
EUVIMED